JP7603061B2 - Ｃｒ２結合タンパク質および医学的治療におけるそれらの使用 - Google Patents

Ｃｒ２結合タンパク質および医学的治療におけるそれらの使用 Download PDF

Info

Publication number
JP7603061B2
JP7603061B2 JP2022513412A JP2022513412A JP7603061B2 JP 7603061 B2 JP7603061 B2 JP 7603061B2 JP 2022513412 A JP2022513412 A JP 2022513412A JP 2022513412 A JP2022513412 A JP 2022513412A JP 7603061 B2 JP7603061 B2 JP 7603061B2
Authority
JP
Japan
Prior art keywords
seq
binding protein
amino acid
acid sequence
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022513412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545947A (ja
JP2022545947A5 (enExample
Inventor
ジェームズ、マシュー、ベイリー
ヘルベン、ボウマ
マイケル、ニール、バーデン
カロライン、ジェイ．ディメッチ
デイビッド、ディクソン
ガブリエラ、ドス、サントス、クルス、デ、マントス
クリスティアン、エルソン
ローラ、ジェイ．フーカ
セムラ、キッチン
エレオノーラ、レコバ
エミリー、マドゥラ
キラン、ニスタラ
チエン、チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2022545947A publication Critical patent/JP2022545947A/ja
Publication of JP2022545947A5 publication Critical patent/JP2022545947A5/ja
Application granted granted Critical
Publication of JP7603061B2 publication Critical patent/JP7603061B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022513412A 2019-08-30 2020-08-28 Ｃｒ２結合タンパク質および医学的治療におけるそれらの使用 Active JP7603061B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1912437.9 2019-08-30
GBGB1912437.9A GB201912437D0 (en) 2019-08-30 2019-08-30 CR2 Binding Proteins and their use in Medical Therapy
PCT/EP2020/074049 WO2021038023A1 (en) 2019-08-30 2020-08-28 Cr2 binding proteins and their use in medical therapy

Publications (3)

Publication Number Publication Date
JP2022545947A JP2022545947A (ja) 2022-11-01
JP2022545947A5 JP2022545947A5 (enExample) 2023-08-31
JP7603061B2 true JP7603061B2 (ja) 2024-12-19

Family

ID=68207176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513412A Active JP7603061B2 (ja) 2019-08-30 2020-08-28 Ｃｒ２結合タンパク質および医学的治療におけるそれらの使用

Country Status (14)

Country Link
US (1) US20230032643A1 (enExample)
EP (1) EP4021938A1 (enExample)
JP (1) JP7603061B2 (enExample)
KR (1) KR20220053000A (enExample)
CN (1) CN114375305A (enExample)
AR (1) AR119865A1 (enExample)
AU (1) AU2020338807A1 (enExample)
BR (1) BR112022003623A2 (enExample)
CA (1) CA3151687A1 (enExample)
GB (1) GB201912437D0 (enExample)
IL (1) IL290649A (enExample)
MX (1) MX2022002478A (enExample)
TW (1) TWI851801B (enExample)
WO (1) WO2021038023A1 (enExample)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP1001021B1 (en) * 1998-09-25 2003-08-27 Wolfgang Prodinger Monoclonal antibody to human CD21, and its uses
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
JP2004529945A (ja) * 2001-05-17 2004-09-30 ラ ホヤ ファーマシューティカル カンパニー Ｃｄ２１を阻害する薬剤を使用して抗体媒介性病理を処置する方法
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
BR112012029067A2 (pt) * 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
WO2016187216A1 (en) * 2015-05-18 2016-11-24 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
WO2017189281A1 (en) * 2016-04-27 2017-11-02 The Regents Of The University Of Michigan C3d cellular and acellular vaccines for the prevention and treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUTHRIDGE, J. M. et al，Epitope Mapping Using the X-Ray Crystallographic Structure of Complement Receptor Type 2 (CR2)/CD21: Identification of a Highly Inhibitory Monoclonal Antibody That Directly Recognizes the CR2-C3d Interface，The Journal of Immunology，2001年，Vol.167(10)，pp.5758-5766

Also Published As

Publication number Publication date
TW202126687A (zh) 2021-07-16
IL290649A (en) 2022-04-01
AU2020338807A1 (en) 2022-03-10
AU2020338807A8 (en) 2022-06-02
CN114375305A (zh) 2022-04-19
EP4021938A1 (en) 2022-07-06
JP2022545947A (ja) 2022-11-01
TWI851801B (zh) 2024-08-11
AR119865A1 (es) 2022-01-19
US20230032643A1 (en) 2023-02-02
GB201912437D0 (en) 2019-10-16
MX2022002478A (es) 2022-03-22
CA3151687A1 (en) 2021-03-04
KR20220053000A (ko) 2022-04-28
WO2021038023A1 (en) 2021-03-04
BR112022003623A2 (pt) 2022-05-24

Similar Documents

Publication Publication Date Title
JP7727387B2 (ja) 新規の抗ｃｄ３９抗体
JP6728053B2 (ja) 抗ｍｃａｍ抗体及び関連する使用方法
EP4289861A1 (en) Antibodies against human tslp and use thereof
JP6126532B2 (ja) 抗ｉｌ−２３抗体
US20220389111A1 (en) High affinity antibodies to cd39 and uses thereof
KR102840867B1 (ko) 치료용 항-cd40 리간드 항체
CA3198102A1 (en) Anti-dectin-1 antibodies and methods of use thereof
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
JP2023528235A (ja) ＳＡＲＳ－ＣｏＶ－２抗体、並びにこれを選択及び使用する方法
KR20160131061A (ko) 항-mcam 항체 및 관련된 사용 방법
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
CN112969714A (zh) 抗cd40抗体、其抗原结合片段及其医药用途
KR20230113752A (ko) Cd39 및 tgf베타를 표적화하는 신규 접합체 분자
CA3097253A1 (en) Antibodies targeting glycoprotein vi
KR20250023381A (ko) C-kit 및/또는 시글렉을 표적화하는 항체 및 이의 용도
CN108473586B (zh) 抗cd27抗体、其抗原结合片段及其医药用途
JP7603061B2 (ja) Ｃｒ２結合タンパク質および医学的治療におけるそれらの使用
JP2022540904A (ja) ヒトｔｒｅｍ－１に対する抗体およびその使用
JP2025508835A (ja) アラーミンに対する二重特異性結合タンパク質およびその使用
KR20220054600A (ko) Il-38-특이적 항체
CA3102329C (en) Novel anti-cd39 antibodies
KR20260025131A (ko) 림포톡신 베타 수용체 작용제 결합 단백질
CN121358778A (zh) Lilrb2结合蛋白及其用途
HK40051457A (en) Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241025

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241209

R150 Certificate of patent or registration of utility model

Ref document number: 7603061

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150